IPF, or idiopathic pulmonary fibrosis, is a chronic lung disease in which the tissue deep inside the lungs becomes progressively scarred and stiff, making it harder and harder to breathe. The median survival after diagnosis is roughly 4 to 5 years, though about a third of patients live longer than five years. It is a rare disease, affecting approximately 18 out of every 100,000 people worldwide, with about 6 new cases per 100,000 diagnosed each year.
What Happens Inside the Lungs
Your lungs contain millions of tiny air sacs called alveoli, where oxygen passes into your blood and carbon dioxide passes out. In IPF, the thin walls of these air sacs become repeatedly injured. Normally, the body repairs such damage cleanly, but in IPF the repair process goes wrong.
Instead of restoring the delicate tissue, the body produces cells called myofibroblasts that lay down thick, stiff scar tissue (collagen) in the walls between air sacs. The cells that line the air sacs die off and are replaced by cells that grow on this abnormal scaffolding, so the original structure never rebuilds properly. Over time, the alveoli collapse and fuse together. The lungs become rigid and shrunken, and less oxygen can reach the bloodstream.
A signaling protein called TGF-beta plays a central role. It can even cause the lung’s own lining cells to transform into scar-producing cells, further accelerating the damage. Immune cells from the bloodstream also migrate to injured areas, differentiate into scar-producing cells, and add to the buildup. The result is a self-reinforcing cycle of injury and scarring that progresses even without an obvious ongoing trigger.
Why “Idiopathic” and Who Gets It
“Idiopathic” means no identifiable cause. Unlike other forms of pulmonary fibrosis linked to asbestos exposure, autoimmune diseases, or radiation, IPF develops without a clear external reason. It overwhelmingly affects adults over 50 and is more common in men than women.
Several factors raise risk. Cigarette smoking is the strongest environmental link. Chronic exposure to metal dust, wood dust, or farming pollutants also increases likelihood. Genetics play a measurable role: a variant in a gene called MUC5B, which affects mucus production in the airways, is found in roughly 10 to 20 percent of people of European descent. Carrying one copy of this variant increases the risk of developing IPF by about 8 times. Gastroesophageal reflux, in which stomach acid repeatedly reaches the lower airways, is another recognized contributor.
Symptoms and How It’s Recognized
IPF typically starts subtly. The earliest symptom is shortness of breath during activities that previously felt easy, like climbing stairs or walking uphill. A persistent, dry cough that doesn’t respond to typical treatments is the other hallmark. Because these symptoms overlap with many common conditions, the average patient sees multiple doctors over one to two years before receiving the correct diagnosis.
On a physical exam, doctors listen for a distinctive crackling sound at the base of both lungs when you breathe in. These are often called “Velcro crackles” because they sound remarkably like tearing apart a strip of Velcro. About half of people with IPF also develop clubbing, a widening and rounding of the fingertips and nails caused by chronic low oxygen levels. A high-resolution CT scan of the chest is the most important diagnostic tool. It reveals a characteristic pattern of scarring, honeycombing, and distortion concentrated in the lower and outer portions of both lungs.
How IPF Progresses
The course of IPF varies considerably from person to person. Some experience a slow, steady decline in lung function over many years. Others deteriorate more rapidly. A smaller group remains relatively stable for extended periods before a sudden worsening.
The most dangerous complication is an acute exacerbation: a rapid, severe flare of breathing difficulty that develops over days to weeks with no identifiable cause like infection or heart failure. New areas of inflammation appear on imaging, and the patient’s oxygen levels drop sharply. In-hospital mortality from an acute exacerbation is close to 50 percent, and median survival after one is only 3 to 4 months. These episodes can strike at any point in the disease and are difficult to predict.
As the disease advances, low blood oxygen becomes constant rather than just exercise-related, requiring supplemental oxygen. Pulmonary hypertension (high blood pressure in the lung’s arteries) develops in many patients as scarring restricts blood flow, eventually straining the right side of the heart.
Treatment With Antifibrotic Medications
No medication reverses the scarring that has already formed, but two antifibrotic drugs can slow the rate of decline. Both work by interfering with the signaling pathways that drive scar tissue production. In clinical practice, these medications roughly cut the monthly loss of lung capacity in half. One study of combination therapy found that the rate of lung function decline dropped from about 27 mL per month to 11 mL per month.
Side effects are common but usually manageable. Gastrointestinal issues (nausea, diarrhea, reduced appetite) are the most frequent complaints and sometimes require dose adjustments. Liver function tests are monitored regularly. The drugs don’t make you feel dramatically better day to day, and their benefit is measured over months and years by slowing what would otherwise be a steeper decline. Starting treatment early, before significant lung function is lost, gives the best chance of preserving breathing capacity.
Pulmonary Rehabilitation
Pulmonary rehabilitation is a structured exercise and education program supervised by respiratory therapists. For IPF patients, it meaningfully improves exercise tolerance. In a randomized trial, patients who completed a rehabilitation program could walk about 61 meters (roughly 200 feet) farther in a six-minute walk test compared to those who didn’t participate. That gain faded somewhat after the program ended, which underscores the importance of continuing regular physical activity long term.
Beyond measurable fitness, rehabilitation helps with the practical side of living with IPF: learning energy-conservation techniques, managing breathlessness during daily tasks, and connecting with others who share the diagnosis. Most programs run 6 to 12 weeks and involve two to three sessions per week.
Supplemental Oxygen and Daily Life
When blood oxygen levels drop below a certain threshold, especially during exertion or sleep, supplemental oxygen becomes necessary. Portable oxygen concentrators allow most people to maintain their routines outside the home. Oxygen doesn’t slow the scarring itself, but it reduces breathlessness, protects the heart from strain, and improves sleep quality and mental clarity.
Fatigue is one of the most underappreciated symptoms of IPF. Even with adequate oxygen levels, the effort of breathing through stiff lungs is physically exhausting. Many patients find that pacing activities, prioritizing sleep, and planning rest periods throughout the day helps preserve quality of life more than any single medication.
Lung Transplantation
For eligible patients, lung transplantation is the only treatment that can restore meaningful lung function. IPF is now the leading reason for lung transplants worldwide. Referral for transplant evaluation is typically considered when lung capacity drops below 80 percent of predicted, when the lungs’ ability to transfer oxygen into the blood falls below 40 percent of normal, or when function is declining despite antifibrotic therapy and supplemental oxygen is needed.
The evaluation process itself takes weeks to months and involves extensive cardiac, physical, nutritional, and psychological assessments. Age, overall fitness, and the absence of other serious medical conditions all factor into candidacy. Wait times vary by region and blood type. After transplantation, recipients take lifelong immunosuppressive medications and require close follow-up, but many experience a dramatic improvement in breathing and daily function that was no longer possible with their scarred lungs.